Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Naval G. Daver
The IMPACT Trials Network for improving outcomes for stem cell transplant patients
Why it is crucial to assess response in multiple myeloma
Carlos Fernandez de Larrea
Is double autologous transplantation in multiple myeloma superior in the age of new agents?